- Merck's Phase 3 HYPERION study of WINREVAIR™ shows positive results for pulmonary arterial hypertension (PAH) treatment.
- WINREVAIR significantly reduces the risk of clinical worsening in PAH patients, with a notable impact among those on double background therapy.
- HYPERION study results to be presented at a future medical meeting, with regulatory submissions forthcoming.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.